EdiGene is a dedicated to the development of genome editing technology for human health. Founded by Wei Wensheng in 2015, EdiGene is backed by investors that include Green Pine Capital, Huagai Capital, IDG Capital, Lilly Asia Ventures, and WI Harper Group. EdiGene is headquartered in Beijing.